Eli Ipp, M.D.
In the past three years, Dr. Ipp has received grant/research support from Pfizer, Inc., R.W. Johnson, and Novo-Nordisk. He has served as a consultant for Novo-Nordisk, SmithKline Beecham Pharmaceutical and Hoechst Marion Roussel. Dr Ipp has also served on the Speakers' Bureau for Novo-Nordisk.
Release Date: 04/16/2000
Termination Date: 04/16/2003
Estimated time to complete: 1 hour(s).
Albert Einstein College of Medicine designates this educational activity for a maximum of 1
AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
 
Educational Objectives
- Discuss the difficulties encountered in switching type 2 diabetic patients to insulin
- List the indications for insulin therapy in type 2 diabetes
- Discuss the different insulins available for treatment of type 2 diabetes
- Discuss combination therapy with oral agents and insulin in type 2 diabetes.